5.3 Acute Venous Thrombosis, DVT and VTE Prophylaxis
Key Takeaways
- Proximal deep vein thrombosis (popliteal vein or above) carries the highest pulmonary embolism risk and always gets therapeutic anticoagulation; isolated distal calf thrombosis in a low-risk asymptomatic patient may instead be followed with serial compression ultrasound at about 2 weeks.
- Apixaban for acute venous thromboembolism is 10 mg PO twice daily for 7 days then 5 mg twice daily; rivaroxaban is 15 mg twice daily for 21 days then 20 mg daily with food. Dabigatran 150 mg twice daily and edoxaban 60 mg daily both require a 5-10 day parenteral lead-in.
- D-dimer has almost no diagnostic value in the cardiac ICU because heart failure, recent MI or surgery, sepsis, IABP, ECMO and age all elevate it; it excludes venous thromboembolism only when pretest probability is low.
- Phlegmasia cerulea dolens (massive iliofemoral thrombosis with a tense, cyanotic, painful limb and failing arterial inflow) is a limb- and life-threatening emergency requiring immediate IV heparin plus catheter-directed or pharmacomechanical thrombectomy.
- Dual antiplatelet therapy is never venous thromboembolism prophylaxis: a post-PCI patient on aspirin plus ticagrelor still needs mechanical or pharmacologic prophylaxis, and intermittent pneumatic compression is contraindicated by an existing acute DVT, severe limb ischemia, open wounds, or recent fasciotomy.
Why Venous Thrombosis Is a Cardiac-ICU Problem
Test-plan item I.B.2 sits inside Cardiovascular Conditions, and the CMC exam approaches venous thromboembolism (VTE) — the umbrella term covering deep vein thrombosis (DVT) and pulmonary embolism (PE) — as a complication the cardiac nurse is expected to prevent, detect early, and then manage anticoagulation for. The cardiac ICU concentrates every arm of Virchow's triad on the same patient simultaneously, which is why VTE incidence here runs far above the general medical ward.
Virchow's Triad in the Cardiac Patient
| Triad element | Cardiac-specific drivers |
|---|---|
| Venous stasis | Low cardiac output and elevated central venous pressure in decompensated heart failure; post-procedure bed rest after femoral access; immobility on mechanical ventilation or intra-aortic balloon pump (IABP); atrial fibrillation with atrial stasis; obesity and right heart failure with venous congestion |
| Endothelial injury | Femoral and radial sheaths; central venous and pulmonary artery (PA) catheters; extracorporeal membrane oxygenation (ECMO) cannulas; transvenous pacing leads; peripherally inserted central catheters (PICCs); repeated venipuncture |
| Hypercoagulability | Systemic inflammation after myocardial infarction and after cardiac surgery; sepsis; malignancy; heparin-induced thrombocytopenia (HIT); estrogen therapy; inherited thrombophilia; the acute-phase response following any cardiac intervention |
Layer on the routine cardiac-ICU practice of prolonged supine bed rest after femoral access and the habit of holding prophylaxis for procedures, sheath removal, or an epidural, and you have the scenario the exam loves: prophylaxis was suspended 48 hours ago and nobody restarted it.
Anatomy Determines Urgency
- Proximal DVT — popliteal, femoral, common femoral or iliac vein. Highest risk of PE and of post-thrombotic syndrome. Always treated with therapeutic anticoagulation.
- Distal (calf) DVT — confined to the peroneal, posterior tibial or anterior tibial veins. Roughly 15% propagate proximally. Anticoagulate the symptomatic patient with low bleeding risk; in an asymptomatic low-risk patient, serial compression ultrasound at about 2 weeks is an accepted alternative to anticoagulation.
- Upper-extremity DVT (UEDVT) — axillary, subclavian, brachiocephalic. In cardiac patients this is overwhelmingly catheter-associated (PICC, central line, PA catheter, pacer or defibrillator leads) rather than the effort-related Paget-Schroetter type. It presents as unilateral arm swelling, a dull neck or shoulder ache, and dilated superficial chest-wall collateral veins. Anticoagulate; a functioning catheter that is still needed can usually stay in place.
The conversion event is what kills. Sudden dyspnea, pleuritic chest pain, unexplained sinus tachycardia, hypoxemia, or syncope in a patient with a known DVT is a pulmonary embolism until proven otherwise, and in a patient with marginal right ventricular reserve after an inferior MI it is poorly tolerated.
A 68-year-old with decompensated heart failure has been supported by an intra-aortic balloon pump through the left femoral artery for 3 days. The left leg is now 4 cm larger in circumference than the right, tense, deeply cyanotic and exquisitely painful, and the dorsalis pedis Doppler signal has become faint. Which action does the nurse anticipate first?
Recognition and Diagnostic Workup
Classic findings — unilateral calf or thigh swelling with a greater than 3 cm circumference difference measured 10 cm below the tibial tuberosity, pitting edema confined to the symptomatic leg, warmth, erythema, dilated superficial veins, and tenderness along the deep venous system — are neither sensitive nor specific. Homans' sign is unreliable and should not drive your assessment or your documentation.
Wells Score for DVT
| Clinical feature | Points |
|---|---|
| Active cancer (treatment ongoing, within 6 months, or palliative) | +1 |
| Paralysis, paresis, or recent plaster immobilization of a lower extremity | +1 |
| Recently bedridden 3 days or more, or major surgery within 12 weeks | +1 |
| Localized tenderness along the distribution of the deep venous system | +1 |
| Entire leg swollen | +1 |
| Calf swelling more than 3 cm larger than the asymptomatic side | +1 |
| Pitting edema confined to the symptomatic leg | +1 |
| Collateral superficial (non-varicose) veins | +1 |
| Previously documented DVT | +1 |
| Alternative diagnosis at least as likely as DVT | -2 |
Interpretation: 0 or less is low probability, 1-2 moderate, 3 or more high. The simplified two-level version calls a score of 2 or more "DVT likely."
Why D-dimer Fails You in the ICU
D-dimer is a fibrin degradation product with high sensitivity and very poor specificity. In the cardiac ICU it is raised by heart failure, recent myocardial infarction, cardiac surgery, sepsis, atrial fibrillation, malignancy, renal impairment, pregnancy, ECMO and IABP circuits, and simply by advancing age. The consequence is blunt: a positive D-dimer in a critically ill cardiac patient tells you almost nothing. It is a rule-out test, and only in a patient with low or moderate pretest probability.
The diagnostic test is whole-leg or proximal compression ultrasound with duplex. Non-compressibility of the vein under probe pressure is the diagnostic finding; loss of respiratory phasicity and absent color flow support it. CT venography or MR venography is reserved for suspected iliac or inferior vena cava (IVC) thrombus that ultrasound cannot visualize.
Phlegmasia Cerulea Dolens
Massive iliofemoral thrombosis obstructing essentially the entire venous outflow of a limb. The leg becomes tense, markedly swollen, and dusky blue-purple with severe pain; venous hypertension eventually exceeds capillary and then arterial inflow pressure, so distal pulses weaken and the limb is threatened. It can progress to venous gangrene and to hypovolemic shock from third-spacing of several liters into the extremity. Management is immediate IV heparin, leg elevation, volume resuscitation, and urgent catheter-directed thrombolysis or surgical/pharmacomechanical thrombectomy. The pale precursor, phlegmasia alba dolens, is white rather than cyanotic. Do not confuse either with acute limb ischemia — in phlegmasia the limb is swollen and engorged, not pale, collapsed and empty.
Superficial Vein Thrombosis
A palpable, tender, erythematous cord along the greater or lesser saphenous vein. It is not automatically benign: if the thrombus is 5 cm or longer, or lies within 3 cm of the saphenofemoral junction, it warrants ultrasound to exclude deep extension and about 45 days of prophylactic-dose fondaparinux 2.5 mg subcutaneously daily or an equivalent. Short, distal, IV-catheter-associated superficial phlebitis is managed with catheter removal, warm compresses, and NSAIDs if not contraindicated.
A patient with a newly diagnosed proximal femoral vein thrombosis has a creatinine clearance of 22 mL/min. Which anticoagulation strategy is most appropriate to initiate?
Treatment: Agents, Adult Doses, and Duration
| Agent | Adult regimen for acute VTE | Monitoring and renal adjustment | CMC pearls |
|---|---|---|---|
| Unfractionated heparin (UFH) | 80 units/kg IV bolus then 18 units/kg/hr, titrated by weight-based nomogram | aPTT 1.5-2.5 times control or anti-Xa 0.3-0.7 units/mL; platelets at baseline then every 2-3 days | Preferred when CrCl is under 30 mL/min, when a procedure is imminent, or with hemodynamic instability. Short half-life; reversed with protamine |
| Enoxaparin | 1 mg/kg SC every 12 hours, or 1.5 mg/kg SC once daily | CrCl under 30 mL/min: reduce to 1 mg/kg SC once daily. Anti-Xa (peak 4 hours post-dose) in obesity, renal impairment, pregnancy | No routine aPTT. Only partially reversed by protamine (roughly 60%) |
| Fondaparinux | Under 50 kg: 5 mg; 50-100 kg: 7.5 mg; over 100 kg: 10 mg SC daily | Contraindicated at CrCl under 30 mL/min | Synthetic factor Xa inhibitor with no reversal agent. An accepted option in stable HIT patients with adequate renal function, but in critical illness, high bleeding risk, or likely urgent procedures ASH 2018 prefers argatroban or bivalirudin for their much shorter duration of effect — and note the CrCl restriction in the adjacent column |
| Apixaban | 10 mg PO twice daily for 7 days, then 5 mg twice daily | No parenteral lead-in; avoid at CrCl under 15 mL/min | Lowest major-bleeding rate among the DOACs in VTE trials and real-world comparisons |
| Rivaroxaban | 15 mg PO twice daily for 21 days, then 20 mg once daily | Take with food (absorption is food-dependent); avoid at CrCl under 15 mL/min | No parenteral lead-in; single-drug approach from day one |
| Dabigatran | 150 mg PO twice daily after 5-10 days of parenteral anticoagulation | Avoid at CrCl under 30 mL/min | Direct thrombin inhibitor; reversed by idarucizumab 5 g IV |
| Edoxaban | 60 mg PO daily after 5-10 days of parenteral anticoagulation; 30 mg daily if CrCl 15-50 mL/min, weight 60 kg or less, or on a potent P-glycoprotein inhibitor | Avoid at CrCl under 15 mL/min | The lead-in requirement is a favorite distractor |
| Warfarin | Overlap with a parenteral agent for at least 5 days and until INR is 2.0 or above for 24 hours; target INR 2.0-3.0 | INR; vitamin K intake consistency | Still required for mechanical valves, antiphospholipid syndrome, and severe renal failure |
Reversal in major bleeding: protamine for heparins, idarucizumab for dabigatran, andexanet alfa or 4-factor prothrombin complex concentrate for apixaban/rivaroxaban/edoxaban, and vitamin K plus 4-factor PCC for warfarin.
Duration of Therapy
- Provoked by a major transient risk factor (surgery, trauma, prolonged immobility, a removable catheter): 3 months, then stop.
- Provoked by a persistent risk factor (active cancer, chronic heart failure, an indwelling device that stays): anticoagulate as long as the risk factor persists.
- Unprovoked proximal DVT or PE: at least 3 months, then extended indefinite therapy if bleeding risk is not high. Reduced extended-phase dosing is apixaban 2.5 mg twice daily or rivaroxaban 10 mg daily.
- Cancer-associated VTE: apixaban, rivaroxaban, edoxaban, or low-molecular-weight heparin; avoid DOACs with luminal gastrointestinal or genitourinary tumors because of bleeding.
Escalated Therapy
Catheter-directed thrombolysis and pharmacomechanical thrombectomy are reserved for iliofemoral DVT of less than 14 days duration with severe symptoms in a patient with low bleeding risk, good function and reasonable life expectancy, and for phlegmasia. Routine lysis of ordinary femoropopliteal DVT does not reduce post-thrombotic syndrome enough to justify the bleeding (the ATTRACT finding).
IVC filters are indicated only when anticoagulation is absolutely contraindicated in the presence of acute proximal DVT or PE, or when recurrent embolism occurs despite documented therapeutic anticoagulation. A filter prevents embolization; it does not treat thrombosis and is not a substitute for anticoagulation. Retrievable filters must be tracked: retrieve as soon as anticoagulation can safely begin, and put the retrieval plan and follow-up appointment in the handoff and the discharge teaching. Unretrieved filters cause caval thrombosis, strut fracture and migration.
Prophylaxis in the Cardiac ICU
| Modality | Regimen | Cautions and contraindications |
|---|---|---|
| Enoxaparin prophylaxis | 40 mg SC daily; 30 mg SC daily if CrCl under 30 mL/min | Timing intervals around neuraxial catheter placement and removal |
| UFH prophylaxis | 5,000 units SC every 8 or every 12 hours | Preferred in severe renal failure; monitor platelets for HIT |
| Fondaparinux prophylaxis | 2.5 mg SC daily | Option with HIT history; not if CrCl under 30 mL/min |
| Intermittent pneumatic compression (IPC) | Continuous, removed only for hygiene and ambulation | Contraindicated with acute existing DVT, acute limb ischemia or severe peripheral artery disease, open wounds or ulcers, dermatitis, skin grafts, recent fasciotomy, and massive leg edema from pulmonary edema |
| Graduated compression stockings | Adjunct only | Never on an ischemic limb; refit as edema shifts; check for tourniquet rolling at the knee |
Exam Traps Worth Memorizing
- Antiplatelet therapy is not VTE prophylaxis. A patient on aspirin plus ticagrelor after PCI still requires mechanical or pharmacologic prophylaxis, because platelet inhibition addresses high-shear arterial thrombus, not the fibrin-rich thrombus that forms in a stagnant vein.
- Therapeutic anticoagulation for atrial fibrillation or a mechanical valve already covers VTE prophylaxis — do not stack prophylactic heparin on top of a therapeutic infusion.
- With a femoral sheath in place, keep the leg straight with the head of bed 30 degrees or less, follow unit policy on applying IPC to the sheathed limb, and resume pharmacologic prophylaxis only after the defined post-removal interval.
- With a neuraxial catheter, anticoagulant timing follows ASRA intervals; monitor for new back pain, lower-extremity weakness, or bowel/bladder dysfunction as signs of spinal hematoma.
Nursing Priorities and Teaching
- Perform a daily bilateral leg assessment with measured calf circumference, symmetry, warmth, tenderness and skin color. Document numbers, not "no edema noted."
- Review every central line, PICC and PA catheter daily for continued necessity. Catheter-days are the single most modifiable upper-extremity DVT risk in this population.
- Mobilize early. Ambulation once anticoagulation is therapeutic is safe, does not increase embolization, and improves symptoms; bed rest is not a treatment for DVT.
- Teach adherence hard for DOACs: their short half-life means a missed dose opens a real thrombotic window, and there is no INR to reveal non-adherence. Reinforce bleeding precautions, avoiding NSAIDs, reporting black stools, hematuria or severe headache, and consistency of vitamin K intake plus INR follow-up for warfarin.
- Set expectations: swelling and heaviness can take months to resolve, and graduated compression is used for symptomatic post-thrombotic syndrome.
A patient is on bed rest 8 hours after femoral sheath removal following PCI and is receiving aspirin 81 mg daily and ticagrelor 90 mg twice daily. The new nurse asks whether venous thromboembolism prophylaxis is needed. Which response is correct?